Welcome to the Brave New Lab

Psylink is a biotechnology company offering a novel solution to psychedelic drug development
Get in touch
Trusted by
Trusted by
Problem [1]

Mental health disorders

Mental health disorders devastate millions of people every day. In these uncertain times, new treatment modalities are in high need.
Problem [2]

Psychedelic manufacturing

Research and development of psychedelic-based drug products is prevented by limited cost-effective material supply.

We are offering a sustainable, scalable, and cost-effective solution to psychedelic drug development

Solution

Biosynthesis

We perform genetic modification of yeast cells in order to recreate the naturally occurring biosynthetic pathway of target molecules.
How it works
Benefits

Benefits summarized

Increasing demand of psychedelics will rely on sustainable, scalable, ethical and economical supply chain. Biosynthesis has many advantages over current alternatives.
1
Yeast cells have unique properties to grow to high densities in inexpensive chemically defined media. Tightly-controlled high-density fermentation process that allows optimal production of target molecules can be directly scaled-up from R&D scale  to industrial scale.
Easy scalable
2
Extraction of psychedelics from natural sources are limited due to high variability in raw material and low content of active compounds within the plant/fungi. Our applied metabolic engineering, that involves both reconstruction of yeast cellular metabolism and introduction of novel metabolic pathways allows high-level biosynthesis of desired molecules.
High yields and productivity
3
Yeast cells are sustainable mini-factories that can grow on cheap non-complex mineral media. This results in reduced production costs compared to chemical synthesis where expensive primary substrates are used and the process is labor intensive.
Cost effective
4
During the process of biosynthesis there is no emission of toxic waste compared to chemical synthesis, as yeasts are maintained on environmentally-friendly supplements.
Lower environmental impact
5
GMP guidelines govern the production of a drug. Biosynthesis performed in a tightly-regulated fermentation process is a GMP compatible and widely used in the pharmaceutical industry for drug production.
GMP friendly
6
Biosynthesis allows to access rare compounds that are hard to harvest due to miniscule amounts in the plant or fungi.
Access to rare compounds

Classic Psychedelics

For millennia our ancestors used psychedelics in rituals and for healing purposes. We are living in unprecedented times when those substances are paving their way into the clinic.

Our biosynthesis platform allows us to produce a wide variety of molecules including the well-known psychedelics and other intermediate components of fungi & plants.
[1]
Tryptamines
Psilocybin,
Psilocin,
Norbaeocystin,
Baeocystin,
DMT,
5-MeO-DMT.
[2]
Ergolines
LSD
[3]
Phenethylamines
Mescaline
MOLECULES

Our platform

Our versatile biosynthesis platform enables to produce classic psychedelics as well as new chemical entities with desired properties.
Read more

Classic Psychedelics

Read more
Coming Soon

Psychedelics inspired molecules

Development timeline

[2021]

License to work with Schedule I substances

[2021]

R&D Laboratory upgrade

[2021-2022]

Psilocybin biosynthesis technology development in yeasts

[2022-2023]

Versatile biosynthesis platform for various classic and next generation psychedelic compounds

[2022-2023]

API grade Psilocybin is ready for market

[2022-2023]

Identify novel psychedelic candidates and build the pipeline of next-gen molecules

[2023-2024]

Collaboration with Research institutions for novel indications

[2023-2024]

Manufacturing additional drug products for Clinical research

team

Science lovers, mind explorers and believers in healthier humanity

Founders
CEO
Laura Korsakova MPharm
LinkedIn icon

8+ years in pharmacology,
cell-based therapy research with exceptional knowledge of psychopharmacology
and psychedelics.

CSO
Evaldas Ciplys PhD
LinkedIn icon

17+ years in the development of protein production technologies in yeast from gene to purified product.

advisors
Advisor
Rokas Peciulaitis
LinkedIn icon
Scientific Advisor
Osvaldas Ruksenas Prof.
LinkedIn icon
Clinical advisor
Robertas Strumila MD
LinkedIn icon
Clinical advisor
Aiste Lengvenyte MD
LinkedIn icon
Email us

Get in touch

Get in touch

Get in touch

Get in touch

Get in touch

Get in touch